Skip to main content
. 2015 Aug 3;6(28):26090–26103. doi: 10.18632/oncotarget.4636

Figure 4. Effects of the combinations of EGFR and Src inhibitors on signal transduction and survival of human NSCLC cell lines.

Figure 4

A. Percent of survival of HCC827, H1975 and H1299 cells treated for 72 hours with different concentrations of saracatinib (for HCC827, H1975) or dasatinib (for H1299), alone or in combination with erlotinib, as measured by MTT assay. The doses of the two drugs used in combination have been chosen as equipotent at inhibiting cell survival. *, 2-sided P < 0.05 versus erlotinib alone; **, 2-sided P < 0.01 versus erlotinib alone. B. Western blot analysis of HCC827, H1975 and H1299 cells treated for 3 hours with saracatinib (for HCC827, H1975) or dasatinib (for H1299), alone or in combination with erlotinib. The maximum doses used in MTT assays have been chosen for Western blot analysis. C. Percent of survival of HCC827, H1975 and H1299 cells treated for 72 hours with different concentrations of saracatinib (for HCC827, H1975) or dasatinib (for H1299), alone or in combination with cetuximab, as measured by MTT assay. *, 2-sided P < 0.05 versus cetuximab alone; **, 2-sided P < 0.01 versus cetuximab alone. D. Western blot analysis of HCC827, H1975 and H1299 cells treated for 3 hours with saracatinib (for HCC827, H1975) or dasatinib (for H1299), alone or in combination with cetuximab. The maximum doses used in MTT assays have been chosen for Western blot analysis. Data represent the mean (± SD) of three independent experiments, each performed in triplicate. Bars, SDs.